2-(4-fluoro-phenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1-aza-cyclododeca[b]naphthalen-4-yloxy)-phenyl]-amide | 1355620-43-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-fluoro-phenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1-aza-cyclododeca[b]naphthalen-4-yloxy)-phenyl]-amide
• 英文别名: 2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-ylcarboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1-azacyclododeca[b]naphthalen-4-yloxy)phenyl]amide；1-(4-fluorophenyl)-N-[3-fluoro-4-(2,5,8,11-tetraoxa-15-azatricyclo[10.8.0.014,19]icosa-1(20),12,14,16,18-pentaen-18-yloxy)phenyl]-2,3-dimethyl-5-oxopyrazole-4-carboxamide
• CAS: 1355620-43-7
• 化学式: C₃₃H₃₀F₂N₄O₇
• 分子量: 632.621
• InChiKey: ACXBXGPXZDQDJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  46
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  112
• 氢给体数：
  1
• 氢受体数：
  11

文献信息

• [EN] NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS HÉTÉROCYCLIQUES FUSIONNÉS CONVENANT COMME INHIBITEURS DE C-MET TYROSINE KINASE
  申请人：ZHEJIANG BETA PHARMA INC

  公开号：WO2012006960A1

  公开（公告）日：2012-01-19

  Certain novel fused quinazoline derivatives of formula (I) as c-Met inhibitors, their synthesis and their uses for treating a c-Met mediated disorder. Methods for treating a c-Met-mediated disorder are also disclosed in the invention.

  某些新型融合喹唑啉衍生物的化学式（I），作为c-Met抑制剂，它们的合成以及用于治疗c-Met介导的疾病的用途。该发明还揭示了治疗c-Met介导疾病的方法。
• Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors
  申请人：Hu Shaojing

  公开号：US20130123286A1

  公开（公告）日：2013-05-16

  Certain novel fused quinazoline derivatives of formula (I) as c-Met inhibitors, their synthesis and their uses for treating a c-Met mediated disorder. Methods for treating a c-Met-mediated disorder are also disclosed in the invention.

  某些新型融合喹唑啉衍生物（化学式（I））作为c-Met抑制剂，它们的合成以及用于治疗c-Met介导的疾病的用途。该发明还公开了治疗c-Met介导的疾病的方法。
• NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS C-MET TYROSINE KINASE INHIBITORS
  申请人：Betta Pharmaceuticals Co., Ltd.

  公开号：EP2593462B1

  公开（公告）日：2016-09-07
• US9242991B2
  申请人：——

  公开号：US9242991B2

  公开（公告）日：2016-01-26